Effect of Juzen-taiho-to on the Serum Alanine Aminotransferase Levels in Patients with HCV-associated Chronic Hepatitis or Liver Cirrhosis.
10.3937/kampomed.54.191
- VernacularTitle:Ｃ型慢性肝疾患（慢性肝炎・肝硬変症）難治例に対する十全大補湯の治療経験
- Author:
Kazuo TARAO
;
Takashi OKAMOTO
;
Kaoru MIYAKAWA
;
Osamu ENDO
;
Norio TARAO
;
Takahiro MASAKI
- Publication Type:Journal Article
- Keywords:
Juzen-taiho-to;
HCV-associated chronic hepatitis;
HCV-associated liver cirrhosis;
alanine aminotransferase
- From:Kampo Medicine
2003;54(1):191-198
- CountryJapan
- Language:Japanese
-
Abstract:
Although the combined administration of glycyrrhizin (SNMC) and ursodeoxycholic acid (UDCA) is usually used for intractable patients with active HCV-associated chronic hepatitis (HCV-CH) or cirrhosis (LC), there are many cases that do not respond to this combination therapy. In this study, we examined the effects of adding Juzen-taiho-to (TJ-48) to lower the serum alanine aminotransferase (s-ALT=s-GPT) levels in such cases. Methods: The average s-ALT levels for 6 months were compared before and after 7.5g of Juzen-taiho-to was added to the combined therapy of SNMC and UDCA for 9 HCV-CH and 12 HCV-LC patients. In some cases, the effectiveness of the therapy over 12 months was also evaluated. Results: In the HCV-CH cases s-ALT levels were significantly decreased in 3 of 9 (33%) cases in 6 months (about 30 INU in average). In the HCV-LC cases, s-ALT levels were significantly decreased in 5 of 12 (42%) cases in 6 months (more than 40 INU in average). There were some patients whose s-ALT levels decreased significantly after 6 months. As to the improvement of clinical symptoms, general fatigability improved in 12 out of 20 cases (60%) and anorexia improved in 10 out of 19 cases (53%). Conclusions: Juzen-taiho-to (TJ-48, 7.5g daily) added to the combined therapy of SNMC and UDCA may be an effective therapy for intractable cases of active HCV-CH or LC.
